Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
about
Clinical Implications of Antiviral Resistance in InfluenzaInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewSafety and efficacy of peramivir for influenza treatmentSerendipitous discovery of a potent influenza virus a neuraminidase inhibitorRisk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivirGenetic Characterization of Circulating 2015 A(H1N1)pdm09 Influenza Viruses from Eastern IndiaRandomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infectionsInhibition of influenza virus replication by targeting broad host cell pathwaysHigh-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase ActivityInfluenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.Drug resistance in influenza A virus: the epidemiology and management.Japanese Surveillance Systems and Treatment for Influenza.The pharmacological management of severe influenza infection - 'existing and emerging therapies'.Influenza virus neuraminidase (NA): a target for antivirals and vaccines.A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.Genomic reassortants of pandemic A (H1N1) 2009 virus and endemic porcine H1 and H3 viruses in swine in Japan.An overview of the characteristics of the novel avian influenza A H7N9 virus in humans.Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 SubtypeBiochemical and structural characterization of the interface mediating interaction between the influenza A virus non-structural protein-1 and a monoclonal antibodyAntiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription.Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution.Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.A cell-based high-throughput approach to identify inhibitors of influenza A virus.E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant RecipientResistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concernInfluenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.Post-influenza aspergillosis, do not underestimate influenza B.The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.Detection of D151G/N mutations in the neuraminidase gene of influenza A (H3N2) viruses by real-time RT-PCR allelic discrimination assay.Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions.Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design.A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.
P2860
Q26782746-F1866C62-8217-4BA1-9825-894F41A64077Q26860032-B86979AB-0771-434D-8B2C-3A6AC14E24BFQ27027408-DB00B9FE-27A7-496E-80E2-CE885E0E9833Q27687973-3DFEBD35-C8E6-4887-9206-C2FFF2B69C04Q28066861-3BAF61D5-E132-4547-BEF4-4C46B5E557EEQ28354086-A2D4A48A-5528-470A-8B5A-BC06401E3E90Q28468567-F9AFA880-4389-4135-8E74-7E84084476B5Q28543978-FE139D88-CBBA-44BB-9E64-818B8409FC5DQ28552500-2CE9F14D-F56F-4609-9979-EAF879A6CA50Q30203367-BF45C25B-489E-445F-A881-2302A4AAAF3BQ30234600-50318EF3-E1CD-46F4-A077-365B720959ACQ30239895-B24FB9F0-9561-4029-921C-05B28D9A457FQ30243907-AA696CA2-0B05-4657-9A2F-6C08977054B1Q30249879-1D83BFEA-15F0-48E1-80EC-0A707FE52705Q30357193-633B05D6-0B64-4B3B-BF07-2009737F1446Q30365051-40F3430A-9833-4133-8F5A-9E9A939EDC47Q30372931-C2D9A935-493F-4523-A21B-B08B8F9F58DAQ30376605-ECFB722D-C6F8-4B94-9B58-01F0140F25E3Q30392999-73AE1312-17DC-4CB1-8E0E-B8B2A66AB87DQ30395244-91EC8DA9-E7D2-4F9F-9154-0441E039E934Q30427798-5F235684-3A03-4DD9-8306-94A1CDA2E9E9Q34044597-B42566A3-7465-425C-8C8C-0E0CD4F63C3BQ34597785-9E66F55C-AD64-4574-967A-31A5990DFAE3Q34762862-38C4DF55-7E82-49D6-99B0-47F25143F0A0Q35755496-E668634D-188F-4170-844C-FAB5E3B4F333Q36237545-388819F5-5A29-4A55-AAE8-7F983E169EC0Q36250190-93A6A85A-4EC3-4438-BB5D-3D680E0528F5Q37074496-472364CF-AD91-4ECF-AB3D-C7BD3ADF7AFDQ37169942-6690C0EC-74B3-4C31-8CA2-E343FA398CC9Q37296019-A2B309BA-C074-44B7-BB83-4A7D992E232BQ37394266-836A37E8-7E77-41C5-95A1-A2BA1771C18AQ37639424-D9EE36AD-8D0B-48BE-8FFB-14887A4EF906Q37671496-8B4ED78D-5602-4E10-A0E8-93C85813C2E8Q37696588-66F3C813-CDC1-4574-96DF-C3405E716738Q38627487-F1113E00-63B8-47CC-A57D-3D4D3189071CQ38724821-AA42B0BB-530E-48EA-A57E-6D1AE3969DFAQ38790676-2CAD02EF-F36C-4934-83DA-80937D78694BQ39152320-8D14D560-C9EE-4A33-844F-9CF882D06F7FQ39296374-32EC6954-176E-47C6-8C01-9045A9029B0CQ40065607-96F4863C-F434-4165-9CF7-BEF9A7DA6BEF
P2860
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@ast
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@en
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@nl
type
label
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@ast
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@en
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@nl
prefLabel
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@ast
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@en
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@nl
P2860
P921
P3181
P356
P1476
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
@en
P2093
Jennifer L McKimm-Breschkin
P2860
P3181
P356
10.1111/IRV.12047
P407
P478
P577
2013-01-01T00:00:00Z